drugset
drugset / Trial / NCT01763931

DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer

NCT01763931 ↗

Phase 2 Completed 6 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins United States Department of Defense · collab
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to learn what effects digoxin (DIG) may have on human breast cancer tissue.

Timeline

Start
2013-01
Primary completion
2016-04-01
Completion
2016-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified — —

Indications

breast cancer